Pharma Doesn't Lose Market Access In the Boardroom.
It Loses It Downstream.
$25 billion in annual revenue disappears at the PA wall — prescription by prescription, silently. Every denied authorization is a patient who never started therapy and a revenue event that never appears in your commercial data. Bridge Agent makes the invisible visible, and then eliminates it.
The scale of the market access problem for pharma
Prescriptions that are written but never filled — the invisible pharma revenue crisis
Content bottleneck that delays every market access initiative and field initiative
Of first-line specialty drug PAs are denied — often for criteria that are clearly met
By which point revenue is gone, patients are on alternatives, and the data is stale
Why Enterprise Pharma Deals Stall — and Where BA Wins Them
Most market access tools sell visibility dashboards. Buying committees aren't screening for dashboards. They're screening for downstream outcomes: fewer lost prescriptions, faster field operations, and zero AE reporting misses.
The Invisible Revenue Leak
When a physician writes a prescription but the PA is denied, the patient abandons therapy. This revenue disappears silently — never showing up in your sales data because the prescription was never filled. Most pharma companies have no visibility into this gap.
MLR Review is a Commercial Bottleneck
Every piece of content your field force uses must survive Medical, Legal, and Regulatory review — a process that takes 6–8 weeks on average. By the time approval comes, the market window has shifted. Competitors have moved. The moment is lost.
No Real-Time Market Access Visibility
Your market access team knows the payer policies in theory. But what is actually happening at the point of prescription — in real time, by drug, by indication, by geography — is invisible. You are making decisions on quarterly reports about problems from three months ago.
Adverse Event Under-Reporting Risk
Medical affairs interactions with healthcare providers generate AE signals daily. Capturing, processing, and reporting within FDA 15-day timelines requires infrastructure most pharma companies are still managing manually. The compliance exposure is significant.
3 Agents. Built for Pharma Operations.
Market access, medical affairs, and medical liaison — each with a dedicated agent architected for pharmaceutical compliance.
Market Access Agent
Real-time PA visibility converted to commercial intelligence.
Medical Affairs Agent
MLR-compliant content and MSL operations at scale.
Medical Liaison Agent
AE signal detection and regulatory reporting — automated.
Built for the Executives Who Own the Downstream Risk
Bridge Agent speaks the language of pharma decision-makers — not pilots and dashboards, but measurable downstream outcomes tied to your commercial, medical, and safety reporting lines.
Payer denials are blocking your drug from reaching patients — and you only find out 90 days later
Real-time PA denial intelligence mapped to your formulary positions
MLR review is the speed limiter on every field initiative. Your MSLs are waiting. The market is moving.
MLR automation that cuts review time while maintaining full compliance governance
Patients abandon therapy at the PA wall. You get the call about the access problem after the patient is already on a competitor.
PA Navigator integration that gives patient services real-time case visibility
The Companies That Close This Gap Win Enterprise Contracts.
Bridge Agent converts invisible PA revenue leakage into recoverable commercial intelligence — in real time. Not quarterly. Not historically. Now.